The Food and Drug Administration has agreed to Pfizer’s request to remove a boxed warning on its medicine prescribed to help people quit smoking.
The company’s Chantix product preceding carried a "black box" warning of potential neuropsychiatric events associated with the drug.
Pfizer (NYSE: PFE) said the removal of the boxed warning was based on positive outcomes from what it described as the largest smoking cessation clinical trial, which involved 8000 patients with and without histories…
Source: bizjournals.com